Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation

@article{Svaldi2001Technetium99msestamibiSA,
  title={Technetium-99m-sestamibi scintigraphy: an alternative approach for diagnosis and follow-up of active myeloma lesions after high-dose chemotherapy and autologous stem cell transplantation},
  author={Mirja Svaldi and C. Tappa and U. Gebert and Dario Bettini and Piero Fabris and F. Franzelin and Luzian Osele and Manfred Mitterer},
  journal={Annals of Hematology},
  year={2001},
  volume={80},
  pages={393-397}
}
Technetium-99m-sestamibi (MIBI) is a radionuclide tracer taken up by different malignant tumors. A total of 88 MIBI scans were carried out in 20 individuals with monoclonal gammopathy of unknown significance (MGUS) and 10 patients during follow-up for other cancers. Of these 58 MIBI scans were carried out in 46 myeloma patients: 15 at diagnosis, 14 during conventional chemotherapy, and 29 following high-dose sequential therapy and autologous peripheral blood progenitor support. A positive MIBI… CONTINUE READING
BETA
Highly Cited
This paper has 32 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 22 REFERENCES

Toward curing myeloma ( MM ) : durable CR in the absence of chromosome 13 deletion and with timely application of two cycles of mel - phalan - based high does therapy ( abstract )

  • B Barlogie, D Ayers, +6 authors E Anaissie
  • 1999

Similar Papers

Loading similar papers…